GLP-1 moiety from Dulaglutide(CAS: 923950-08-7)

GLP-1 moiety from Dulaglutide (CAS: 923950-08-7) is a crystalline compound with a molecular weight of approximately 1290 Da. It is poorly soluble in water but more soluble in organic solvents like DMSO. The compound exhibits moderate reactivity, particularly with nucleophiles and bases, making it susceptible to hydrolysis under alkaline conditions. Care should be taken to store and handle it under basic storage conditions to minimize degradation.

The GLP-1 moiety from Dulaglutide (CAS: 923950-08-7) is typically synthesized through solid-phase peptide synthesis (SPPS) using Fmoc chemistry. Commonly, the process involves stepwise assembly of protected amino acids on a solid support, followed by cleavage with strong acids like trifluoroacetic acid (TFA). The final product is then purified by reverse-phase HPLC, ensuring high purity and yield. The synthesis process requires careful control of pH and temperature to maintain optimal reactivity and selectivity.

GLP-1 moiety from Dulaglutide (CAS: 923950-08-7) is primarily used in the pharmaceutical industry, particularly in the development and production of GLP-1 receptor agonists like dulaglutide, a treatment for type 2 diabetes. It can also be applied in research and development for studying GLP-1 biology and for the production of related peptides. The compound's role in diabetes treatment highlights its significance in the health and biotech industries.

When handling GLP-1 moiety from Dulaglutide (CAS: 923950-08-7), proper personal protective equipment (PPE) should be worn, including gloves, goggles, and a lab coat. Work should be conducted in a well-ventilated fume hood to minimize inhalation risks. Spills should be handled with care using appropriate absorbent materials, and the area should be thoroughly cleaned. Safety data sheets (SDS) should be readily available for reference, and in case of any spills or exposures, emergency procedures should be followed immediately.